GS-US-312-0123 : Essai de phase 3 randomisé, en double-aveugle, visant à évaluer l’efficacité et la tolérance de l’idélalisib associé à la bendamustine et au rituximab, chez des patients ayant une leucémie lymphoïde chronique non précédemment traitée. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’idélalisib en association avec de la bendamustine et du rituximab, chez des patients ayant une leucémie lymphoïde chronique. Le...

• Pays France
• Organes Leucémies chroniques
• Spécialités Thérapies Ciblées, Chimiothérapie

An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after liver transplantation The primary objectives of this study are: • To explore the antiviral efficacy of combination therapy with SOF/LDV FDC + RBV for 12 or 24 weeks in subjects with advanced liver disease (either pre-liver...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E) The primary objective of this study is to evaluate the long-term safety of darusentan in subjects with RHTN despite treatment with full doses of three or more antihypertensive medications, including a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study in people with long-lasting hepatitis B to assess the effectiveness and safety of the two drugs Viread and Hepsera. Sudio su persone affette da epatite B da lungo tmepo per valutare l`efficacia e la sicurezza dei due farmaci Viread e Hepsera -To compare the efficacy of tenofovir DF 300 mg QD versus adefovir dipivoxil 10 mg QD for the treatment of presumed pre-core mutant chronic hepatitis B. •To compare the safety and tolerability of te...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3 Randomized, Double-Blind, Placebo-controlled study of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated CLL To evaluate the effect of the addition of idelalisib (formerly GS-1101) to rituximab on progression-free survival (PFS) in subjects with previously treated chronic lymphocytic leukemia (CLL).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction The primary objective of the study is to determine if ranolazine, compared to placebo, will be more effective in improving diastolic function in patients with HFpEF.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the proportion of subjec...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection. The purpose of this study is to evaluate safety, and to determine whether GS-9883/F/TAF as a fixed dose combination maintains the control of HIV-1 infection effectively compared to treatment with dolutegravir (DTG) (trade name Tivicay) and emtricitabine/tenofovir alafenamide (F/TAF) To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Clinical research study involving an experimental combination medication called EVG/COBI/FTC/TDF. This is 1 pill containing 2 experimental medications, EVG and COBI, plus 2 medications already approved for the treatment of HIV-1 infection, FTC and TDF. In this study neither the patient or the investigator will know whether the patient is receiving EVG/COBI/FTC/TDF or the comparator drug ritonavir-boosted atazanavir with FTC/TDF. This is a randomized (by chance, like a flip of a coin) study To evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumara...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study with sofosbuvir and ribavirin for people with Hepatitis C and severe kidney disease The primary objectives of this study are: * To evaluate the safety of sofosbuvir (SOF) 200mg or 400mg + ribavirin (RBV) for 24 weeks as assessed by review of the accumulated safety data in each treat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune